Kemin launches Neumentix phenolic complex

Kemin launches Neumentix phenolic complex

Neumentix Phenolic Complex K110-42 is sourced from patent-pending, non-GMO lines of Kemin’s purpose-grown spearmint for use in cognitive support supplements.

Kemin is pleased to launch Neumentix™ Phenolic Complex K110-42, a proprietary phenolic complex sourced from patent-pending, non-GMO lines of Kemin Industries’ own purpose-grown spearmint for use in dietary supplements.

Around the world, people are living and working longer than ever before, and more people are looking to optimize their cognitive health to help them perform better. A recently completed clinical trial has shown Neumentix can provide natural support for an important component of cognitive performance—working memory—and offer other related benefits.

“The market for cognitive health products is growing rapidly worldwide, and we are very excited about these new clinical results and the launch of Neumentix,” said Linda Fullmer, senior vice president of sales and marketing for the human nutrition and health division of Kemin. “Consumers are concerned about staying mentally sharp and maximizing performance, and they need safe, clinically supported products to address these concerns.”

Kemin Industries’ Phenolic Complex K110-42 is derived from patent-pending, non-GMO lines of spearmint developed by Kemin plant scientists using traditional plant-breeding methods. The company’s patent-pending lines of spearmint are grown in the USA on family farms that have been passed down from generation to generation.

In a 12-week randomized, double-blind, placebo-controlled study in adults with age-associated memory impairment using the Cognitive Drug Research Battery, a standardized and validated testing battery that has been used in multiple clinical studies, subjects who took Neumentix showed better overall quality of working memory compared to subjects who took placebo. This data suggests, when taken as directed, Neumentix helps to improve cognitive performance in adults. In addition, people taking Neumentix also reported that they got to sleep easier and faster at night according to the validated Leeds Sleep Evaluation Questionnaire used in the study.

The safety of Neumentix is supported by 14- and 90-day repeated-dose feeding studies in rats, Ames mutagenicity and chromosomal aberration genotoxicity studies and a 30-day human tolerability study conducted with the ingredient.

Kemin will be sharing this clinical research as well as the body of data supporting Neumentix at SupplySide West. For more information, please stop by Kemin booth #18109 or contact your Kemin representative.


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.